{"id":"NCT03998436","sponsor":"Novalead Pharma Private Limited","briefTitle":"Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers","officialTitle":"A Prospective, Multicenter, Randomized, Double-Blind, Phase 3 Study to Evaluate the Safety and Efficacy of a Gel Formulation of Esmolol Hydrochloride (Galnobax®) in Treating Diabetic Foot Ulcers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-26","primaryCompletion":"2021-08-19","completion":"2021-12-06","firstPosted":"2019-06-26","resultsPosted":"2023-09-22","lastUpdate":"2023-09-22"},"enrollment":176,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Foot Ulcer"],"interventions":[{"type":"DRUG","name":"Esmolol Hydrochloride","otherNames":["Galnobax"]},{"type":"OTHER","name":"Only Standard of Care","otherNames":[]},{"type":"OTHER","name":"Vehicle Gel","otherNames":[]}],"arms":[{"label":"Galnobax® 14% gel plus SoC","type":"ACTIVE_COMPARATOR"},{"label":"SoC Only","type":"SHAM_COMPARATOR"},{"label":"Vehicle plus SoC","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the current Study is to determine the safety and effectiveness of Galnobax® plus Standard of Care versus only Standard of Care, in treating Diabetic Foot Ulcers (DFU). In addition, Study is designed to investigate the safety of Galnobax® vehicle for establishing non-deleterious effects of Vehicle on wound healing in the Subjects with DFU. The study is being conducted in 350 subjects being recruited in about 30 centers in India.","primaryOutcome":{"measure":"Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator","timeFrame":"Wound closure assessed up to week 12 and confirmed by 2 visits 2 weeks apart; only participants with wound closure at or before Week 12 and who maintained closure after 4-weeks of follow-up reported","effectByArm":[{"arm":"Galnobax® 14% Gel Plus SoC","deltaMin":41,"sd":null},{"arm":"SoC Only","deltaMin":30,"sd":null},{"arm":"Vehicle Plus SoC","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0276"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["India"]},"refs":{"pmids":["37184839"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":76},"commonTop":["Hypertension","Cellulitis","Wound complication","Urinary tract infection","Wound infection"]}}